ITACA Ⅲ期试验:药物基因组学指导辅助化疗对比标准化疗治疗完全切除的Ⅱ-ⅢA期非小细胞肺癌
中位随访45.9个月时,T组与C组的5年生存率分别为72.9%与65.4%,HR为0.77(95%CI 0.56-1.06,P=0.109),差异无统计学意义;T组3-5级毒性发生率更低。
要点
- 按ERCC1/TS mRNA表达行个体化辅助化疗,OS呈有利于T组的非显著趋势(HR 0.77,P=0.109)。
- T组5年生存率72.9%,C组65.4%,中位随访45.9个月。
- T组3-5级毒性更少,实验组疗效/毒性比更优。
核心结论
- 在完全切除的Ⅱ-Ⅲ期NSCLC中,基于ERCC1与TS mRNA表达水平的个体化辅助化疗较标准化疗显示出有利于T组的OS趋势,但未达统计学显著。
- T组与C组相比,在安全性方面与实验组不同治疗选择相关的疗效/毒性比更优。
研究设计与样本
- 按ERCC1与TS mRNA表达水平分为四个基因组亚组,在各亚组内随机分配至研究者选择的含铂化疗(C)或个体化化疗(T)。
主要发现
- 中位随访45.9个月时,C组85例(24.6%)、T组70例(20.3%)死亡。
- C组与T组5年生存率分别为65.4%(95%CI 58.5%-71.4%)与72.9%(95%CI 66.5%-78.3%)。
- T组对比C组的OS HR为0.77(95%CI 0.56-1.06,P=0.109);无复发生存HR为0.89(95%CI 0.69-1.14,P=0.341)。
- 3-5级毒性在C组报告更频繁。
关键数值与推荐
- OS主要分析:T组对比C组HR 0.77(95%CI 0.56-1.06,P=0.109)。
- 无复发生存:T组对比C组HR 0.89(95%CI 0.69-1.14,P=0.341)。
- 5年生存率:C组65.4%(95%CI 58.5%-71.4%),T组72.9%(95%CI 66.5%-78.3%)。
临床怎么用
- 对完全切除的Ⅱ-Ⅲ期NSCLC,可依据ERCC1与TS mRNA表达水平选择辅助化疗药物,以期在维持疗效的同时降低3-5级毒性。
- 与标准化疗相比,个体化辅助化疗的OS获益尚未达统计学显著,因此不应据此改变现有辅助化疗标准。
- 实验组因治疗选择不同而呈现更优的疗效/毒性比,支持在临床决策中综合权衡获益与毒性。
局限性
- 主要终点OS的组间差异未达统计学显著(P=0.109)。
- 原文摘要未报告各基因组亚组的疗效及具体化疗方案信息,相关结论不能外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small-cell lung cancer (NSCLC). In this investigator-initiated study we aimed to evaluate the predictive utility of the messenger RNA (mRNA) expression levels of excision repair cross complementation group 1 (ERCC1) and thymidylate synthase (TS) as assessed in resected tumor. PATIENTS AND METHODS: Seven hundred and seventy-three completely resected stage II-III NSCLC patients were enrolled and randomly assigned in each of the four genomic subgroups to investigator's choice of platinum-based chemotherapy (C, n = 389) or tailored chemotherapy (T, n = 384). All anticancer drugs were administered according to standard doses and schedules. Stratification factors included stage and smoking status. The primary endpoint of the study was overall survival (OS). RESULTS: Six hundred and ninety patients were included in the primary analysis. At a median follow-up of 45.9 months, 85 (24.6%) and 70 (20.3%) patients died in arms C and T, respectively. Five-year survival for patients in arms C and T was of 65.4% (95% CI (confidence interval): 58.5% to 71.4%) and 72.9% (95% CI: 66.5% to 78.3%), respectively. The estimated hazard ratio (HR) was 0.77 (95% CI: 0.56-1.06, P value: 0.109) for arm T versus arm C. HR for recurrence-free survival was 0.89 (95% CI: 0.69-1.14, P value: 0.341) for arm T versus arm C. Grade 3-5 toxicities were more frequently reported in arm C than in arm T. CONCLUSION: In completely resected stage II-III NSCLC tailoring adjuvant chemotherapy conferred a non-statistically significant trend for OS favoring the T arm. In terms of safety, the T arm was associated with better efficacy/toxicity ratio related to the different therapeutic choices in the experimental arm.
引用
- Novello S, Torri V, Grohe C, et al. International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. Ann Oncol. 2021. PMID: 34624497. doi:10.1016/j.annonc.2021.09.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。